3° SESSION

SPEAKERS AND MODERATORS

18 NOVEMBER 2006

Pharmacogenetics and Pharmacogenomics application to the paediatric population-1
Chair: A.Iolascon, GP. Tonini

9.15 **Antimetastatic drugs**
M. Zollo

9.30 **HDAC Inhibitors proapoptotic treatment of neuroblastoma**
A.De Ambrosis

9.45 **Proteins acetylation, not only genic expression regulation**
F. Della Ragione

10.00 **Chimeric lymphocytes models**
P. Paolucci – M. Dominici
10.15 Open Discussion

10.45 ***Coffee break***

Pharmacogenetics and Pharmacogenomics application to the paediatric population-2
Chair: F. Salvatore

11.15 **Therapeutic peptides and treatment of neuroblastoma**
A.Pession-R.Tonelli

11.45 **New therapeutic approaches in paediatric oncology**
G. Basso

12.05 **Pharmacogenetics and SNC**
R.Riccardi

12.25 **Drugs with molecolar targets**
F.Pane

12.35 Open Discussion
13.05 ***Conclusion***
F.Salvatore

Andrea Ballabio	Napoli
Giuseppe Basso	Padova
Mario Capasso	Napoli
Silvio Cavalcanti	Bologna
Adriana Ceci	Pavia
Giuseppe Cirino	Napoli
Alessandro de Ambrosis	Genova
Oscar Della Pasqua	Leiden
Fulvio Della Ragione	Napoli
Diego Di Bernardo	Napoli
Roberto Di Lauro	Ariano Irpino
Massimo Dominici	Modena
Achille Iolascon	Napoli
Catherjine Knibbe	Leiden
Gianni Marone	Napoli
Pino Nisticò	Londra
Giuseppe Novelli	Roma
Fabrizio Pane	Napoli
Paolo Paolucci	Modena
Andrea Pession	Bologna
Kerry Rhoden	Bologna
Riccardo Riccardi	Roma
Amin Rostami	Sheffield
Armido Rubino	Napoli
Francesco Salvatore	Napoli
Dick Tibboel	Rotterdam
Roberto Tonelli	Bologna
Gian Paolo Tonini	Genova
Nicola Zambrano	Napoli
GianLuigi Zaza	Bari
Massimo Zollo	Napoli

Scientific Committee:
Adriana Ceci - Oscar della Pasqua
Achille Iolascon - Massimo Zollo

Organizational Secretariat:
Elisa Cattani – Cristina Manfredi
Consorzio per Valutazioni Biologiche e Farmacologiche
Via Palestro 26 - 27100 Pavia
Tel. 0382-25075/25301 - Fax 0382-536544

PHARMACOGENETICS TOOLS IN PAEDIATRIC RESEARCH
A HIGH LEVEL TRAINING COURSE

Promoted by
CEINGE, University Federico II of Naples
Scuola di Specializzazione in Genetica Medica
Supported by
TEDDY Network of Excellence

Naples, 17 & 18 November 2006

CEINGE Biotecnologie Avanzate,
Via Comunale Margherita, 482
Napoli



CME credited course

Background and aim of the meeting

Many disease processes affecting newborns (e.g. congenital infections) and diseases of childhood (e.g. Kawasaki's disease) have no adult correlations. Similarly, acute lymphoblastic leukemia, Wilm's tumour and neuroblastoma are all mainly encountered during childhood, and rarely in adults. New models and methodologies will therefore be proposed in order to assess relevant paediatric pharmacological and toxicological parameters leading to the development of treatments specifically tailored for children.
Knowledge generated by sequencing the human genome will enable more effective strategies to prevent, diagnose and treat human diseases, thus decreasing morbidity and mortality. Together with other age groups, children as well should benefit from this epoch-making breakthrough.

The present event is aimed at:

1- Underlining the role of pharmacogenetic and pharmacogenomics (Ph/Pg) research in order to elucidate the developmental events that could affect diseases and drug treatment responses in children.

2- Facilitating the integration of European groups involved in (paediatric) pharmacogenomics and pharmacogenetics

3- Supporting standardisation of pharmacogenomics and pharmacogenetics tools for evaluating drug response in children (including protocols, methods and approaches)

The event will also provide a high level training course open to research community, regulatory Agencies representatives and Industry.

1° SESSION

17 NOVEMBER 2006

The role of Pharmacogenetics and Pharmacogenomics in drug research and development
Chair: G. Cirino – P. Nisticò

10.00 Introduction to the first session
A. Ballabio

10.15 Introduction to Pharmacogenomics
K Rhoden

10.45 Proteomic approach to pharmacogenomics
N. Zambrano

11.15 Animal models and pharmacogenomics
R. Di Lauro

11.45 Pharmacogenomics and Pharmacogenetics for paediatric drugs development in the 'Teddy' project perspectives
A.Ceci

12.00 Pharmacogenetics: Regulatory aspects and perspectives
G. Novelli

12.30 Open Discussion

13.00 *Lunch*

2° SESSION

Polymorphism and drug response
Chair: A. Rubino

14.15 The IFN experience
M. Capasso

14.30 Research of pharmacological targets
D.Di Bernardo

14.45 Pharmacological interaction studies by computer
S. Cavalcanti

15.00 Pharmacogenetics and allergic disorders
F. Marone

15.15 Pharmacogenomics and kidney
GL.Zaza

15.30 Open Discussion

16.00 ***Coffee break***

Drugs response and Ph/Pg in children
Chair: O. Della Pasqua

16.15 Introduction
O. Della Pasqua

16.30 PGx in critically ill children
D. Tibboel

16.45 PGx as covariates for exposure in young children
C. Knibbe

17.00 Rationale for pediatric dose selection: the advantages and limitations of *in silico* and *in vitro* data
A. Rostami